Revelation Biosciences Q4 net loss widens

Revelation Biosciences

26/02/2026 22:00

Overview

Life sciences firm's Q4 net loss widens yr/yr due to increased operating expenses

Company's cash position improves to $10.7 mln, sufficient to fund operations into Q1 2027

Company advances Gemini program for kidney disease treatment

Outlook

Revelation expects current cash reserves to fund operations into Q1 2027

Company to present Gemini clinical data at conference in March 2026

Result Drivers

OPERATING EXPENSES - Increased to $2.57 mln from $1.75 mln due to more than 50% increase in R&D expenses and a 40% increase in general and administrative expenses

Company press release: ID:nACSs06Y2a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$1.65
Q4 Net Income
-$2.51 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Revelation Biosciences Inc is $85.00, about 5,928.4% above its February 25 closing price of $1.41

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)